This feature highlights changes in clinical trial organizations’ personnel.

Affinia Therapeutics

Petra Kaufmann, gene therapy development expert and previous senior vice president and head of clinical development at Novartis Gene Therapies, has joined Affinia Therapeutics as its newest chief medical officer. Charles Albright, former executive vice president and chief scientific officer at Editas Medicine, has also joined Affinia as its newest chief scientific officer.

Artelo Biosciences

Andrew Yates has been appointed senior vice president and chief scientific officer of Artelo Biosciences. Most recently, Yates held various roles involved in development and commercial strategy as well as medical affairs at AstraZeneca.

Athersys

Gil Van Bokkelen has stepped down from his role of CEO at Athersys. In his place, the company has appointed chief operating officer William Lehmann as interim CEO. Prior to joining Athersys in 2001, Lehmann was involved in McKinsey & Co.’s Business Building practice.

BioCardia

Sujith Shetty, BioCardia’s vice president of clinical and regulatory, has assumed the role of chief medical officer. Prior to his time at BioCardia, Shetty was vice president of clinical and regulatory at Vascular Dynamics.

BioDelivery Sciences

Terry Coelho, BioDelivery Sciences’ chief financial officer, has been promoted to executive vice president. Prior to joining BioDelivery, Coelho was chief financial officer and treasurer at Balchem.

Connectyx

I. Richard Garr, former CEO of Neuralstem, has been appointed CEO of Connectyx. Another new appointment made at Connectyx is Ron Bordens to executive vice president of technical operations and manufacturing. Bordens previously held the same role at Curative Biotech.

Elligo Health Research

Elligo Health Research has made several appointments to the company’s leadership team, including Katie Eyestone to vice president of healthcare partnerships, Kathleen Fairall to chief people officer and Vanessa Watson to vice president of practice success. Eyestone was previously the chief transformation officer at HSS, Fairall was principal at Act III Consulting and Watson most recently served as director of site communications and strategic development at Optimal Research.

Flagship Pioneering

Diego Miralles has been tapped by Flagship Pioneering to serve as the company’s new CEO-partner. Miralles previously served as CEO of Vividion Therapeutics.

jCyte

jCyte has appointed Samir Mody to chief commercial officer, Friedrich Asmus to senior vice president of clinical development and medical affairs and Joel Centeno to senior vice president of manufacturing, quality and supply chain. Previously, Mody served as vice president of CRHF strategy, health economics and reimbursement at Medtronic, Asmus was the vice president of clinical development at ProQR Therapeutics and Centeno was senior vice president of regulatory, quality and U.S. operations at Epigenomics.

Life Biosciences

Joan Mannick, who was the co-founder and chief medical officer at Adicet Bio, has been named head of R&D at Life Biosciences.

Lyra Therapeutics

Robert Kern has been named chief medical officer of Lyra Therapeutics. Kern will continue in his current role of the George A. Sisson professor and chair of the Department of Otolaryngology – Head and Neck Surgery at Northwestern University Feinberg School of Medicine.

Maxwell Biosciences

Maxwell Biosciences has named Sheetal Vali the company’s new director of drug development. Vali most recently served as head of drug development at AROG Pharmaceutical.

Parker Institute for Cancer Immunotherapy

Ute Dugan has been named senior vice president of clinical research of Parker Institute for Cancer Immunotherapy. Previously, Dugan served as head of worldwide oncology external medical affairs at Bristol Myers Squibb.

Penrose TherapeuTx

Bhardwaj Desai has been named chief development officer of Penrose TherapeuTx. Prior to this appointment, Desai served as a clinical oncology consultant and was the global medical lead for oncology at Astellas Pharma.

PolyPeptide Group

Raymond De Vré has been named the new CEO of PolyPeptide Group. Previously, De Vré was senior vice president and head of biologics at Dr. Reddy’s Laboratories.

Surface Oncology

Robert Ross has been named president and CEO of Surface Oncology. Ross has served as the company’s chief medical officer since 2016 and was formerly the head of oncology at bluebird bio.